After encouraging results from melanoma and NSCLC, the pan-cancer efficacy of Dabrafenib (BRAF inhibitor) and Trametinib (MEK inhibitor) has been evaluated in the Rare Oncology Agnostic Research (ROAR) trial, which indicated clinically meaningful responses in anaplastic thyroid carcinoma (ORR, 56%), biliary tract cancer (ORR, 47%), and gliomas (ORR, 31% for high grade, 69% for low grade), leading toward the approval and recommendation of the dual blockade in the pan-cancer BRAF V600E mutation-positive setting [14,28,84,85,86,87,88]. Here, BRAF is linked to central nervous system cancer.